Race Oncology Limited (ASX: RAC) (Race) is pleased to release an updated
investor presentation and invite investors to join a special online investor briefing.

Updated Presentation

• An update on the Company’s Three Pillar strategy and recent related highlights
• Updates to the Board and extended team slides
• Additional information on the FTO pathway (Pillar 1) for Bisantrene, including relevant comparators
• Coming milestones and the expected activity timeline for Bisantrene’s continued development

Investor Briefing Invitation

Investors are invited to attend a special briefing session where Managing Director and CEO, Phillip Lynch and CSO and Executive Director, Dr Daniel Tillett will discuss progress on the Company’s Three Pillar strategy, as well as the recently announced capital raise and Bonus Options Issue. Details as follows: